A compound having the structural Formula (1), or a pharmaceutically acceptable salt thereof for use in the treatment of ADHD comprising the administration of a therapeutically effective amount of a compound having Structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal that requires treatment: wherein: R is selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, CI, Br and I, alkoxy of 1 to 3 carbon atoms, a nitro, hydroxy, trifluoromethyl and thioalkoxy group of 1 to 3 carbon atoms； x is an integer from 1 to 3, with the proviso that R can be the same or different when x is 2 or 3； R1 and R2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms； R1 and R2 may be linked to form a 5-7 membered heterocycle, substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom , and the nitrogen atoms are not directly connected to the oxygen atom.Un compuesto que tiene Ia Fórmula estructural (1), o una sal farmacéuticamente aceptable del mismo para uso enel tratamiento de ADHD que comprende la administración de una cantidad terapéuticamente efectiva de uncompuesto que tiene Fórmula estructural (1) o una sal farmacéuticamente aceptable del mismo, a un mamífero querequiera del tratamiento: en donde: R se selecciona del grupo que consiste de hidrógeno, alquilo inferior de 1 a 8 átomos de carbono, halógenoseleccionado de entre F, CI, Br y I, alcoxi de 1 a 3 átomos de carbono, un grupo nitro, hidroxi, trifluorometilo ytioalcoxi de 1 a 3 átomos de carbono； x es un entero de 1 a 3, con la condición de que R puede ser igual o diferente cuando x es 2 o 3； R1 y R2 pueden ser iguales o diferentes entre si y se seleccionan independientemente del
